Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

Core Viewpoint - Evoke Pharma, Inc. is expanding access to its GIMOTI nasal spray for diabetic gastroparesis through strategic partnerships with Omnicell and Brentwood Pharmacy, aiming to enhance patient care and streamline access to treatment [1][2][3]. Company Overview - Evoke Pharma, Inc. is a specialty pharmaceutical company focused on developing treatments for gastrointestinal disorders, particularly GIMOTI, a nasal spray formulation of metoclopramide for adults with acute and recurrent diabetic gastroparesis [4][5]. Strategic Partnerships - The partnership with Omnicell is expected to nearly double the number of specialty pharmacies that can access GIMOTI, aligning with large gastroenterology practices like Gastro Health, which operates in 7 states and has 150 locations [2][3]. - The agreement with Brentwood Pharmacy, affiliated with OneGI, enhances access to GIMOTI across multiple states, including Tennessee, Kentucky, Ohio, and Mississippi, and supports rapid delivery and additional insurance plan access for patients [3][4]. Market Context - Diabetic gastroparesis is a significant gastrointestinal disorder affecting millions globally, characterized by delayed gastric emptying, which can complicate the absorption of orally administered medications [5]. - GIMOTI is the only FDA-approved treatment for diabetic gastroparesis in the United States, previously available only in oral and injectable forms [5]. Industry Collaboration - EVERSANA, a provider of global commercial services to the life sciences industry, is supporting Evoke in its strategy to improve patient access and streamline the integration with specialty pharmacies [1][12]. - Gastro Health and OneGI are key players in the gastroenterology space, providing extensive networks of physicians and specialized care, which Evoke aims to leverage through its partnerships [13][14].